Q-omics provides the consensus-scored NCOA4P2 profile across patient tissues and cancer cell-line models. NCOA4P2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NCOA4P2 is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, NCOA4P2 RNA expression shows 15,081 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KICH, UCEC, and THYM as cancer lineages where NCOA4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCOA4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCOA4P2 survival associations across molecular data types. NCOA4P2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCOA4P2 RNA expression–survival associations across cancer types. High NCOA4P2 expression shows unfavorable associations in KICH and LUSC, but favorable associations in UCS, LUAD, MESO and STAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for NCOA4P2 RNA expression.
This table summarizes NCOA4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for NCOA4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCOA4P2 shows lower tumor expression in UCEC, BRCA, COAD, LUAD, THCA and LUSC. The UCEC box plot shows higher NCOA4P2 RNA expression in normal versus tumor tissue (log2 FC = −0.181, t-test p < 0.001).
This table shows molecular features associated with NCOA4P2 in patient tissues and cancer cell lines. In patient samples, NCOA4P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
